PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
32.68%
Net income growth of 32.68% while GNPX is zero at 0.00%. Bruce Berkowitz would see a modest advantage that can compound if well-managed.
80.19%
D&A growth of 80.19% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
-398.37%
Negative yoy deferred tax while GNPX stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
30.65%
SBC growth of 30.65% while GNPX is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
27.89%
Working capital change of 27.89% while GNPX is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might affect near-term cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.29%
Negative yoy AP while GNPX is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
66.06%
Growth of 66.06% while GNPX is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
30.65%
Growth of 30.65% while GNPX is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-19.98%
Negative yoy CFO while GNPX is 0.00%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-32.37%
Negative yoy CapEx while GNPX is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-271.58%
We reduce yoy invests while GNPX stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
69.11%
Debt repayment growth of 69.11% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-69.14%
Negative yoy issuance while GNPX is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.